12. Frishman WH, Cheng-Lai A, Nawarskas J. Current Cardiovascular Drugs. Current Science Group; 2005: Arcangelo VP, Peterson AM.

(1)

53

1. Price SA, Wilson LM. Disfungsi Mekanis Jantung dan Bantuan Sirkulasi. Dalam : Hartanto H, Susi N, Wulansari P, Maharani DA, editor. Patofisiologi : Konsep Klinis Proses-Proses Penyakit Edisi 6. Jakarta: EGC; 2003: 632. 2. Guyton AC, Hall JE. Gagal Jantung. Dalam : Rachman LY, Hartanto H,

Novrianti A, Wulandari N, editor. Buku Ajar Fisiologi Kedokteran Edisi 11. Jakarta: EGC; 2006: 271.

3. Fuster V, Walsh RA, Harrington RA. Pathophysiology of Heart Failure. Hurst's The Heart 13th Ed : McGraw Hill; 2011: 721.

4. Longo D, Fauci A, Kasper D, Hauser S, Jameson J, Loscalzo J. Heart Failure and Cor Pulmonale. Harrison's Principles of Internal Medicine 18th Ed : McGraw Hill; 2011: 1901.

5. Firmansyah D. Asuhan Keperawatan Dengan Gagal Jantung di Ruang Sakura RSUD Sragen. Fakultas Keperawatan Universitas Muhammadiyah Semarang. 2009: 1-2.

6. Fuster V, Walsh RA, Harrington RA. The Epidemiology and Diagnosis of Heart Failure. Hurst's The Heart , 13th ed. : McGraw Hill; 2011: 739.

7. Braunwald E. Heart Failure and Cor Pulmonale. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, editors. Harrison’s Principle of Internal Medicine . 16th Edition. New York: McGraw Hill; 2005: 535.

8. Hersunarti N. Pedoman Diagnosis dan Pengobatan Gagal Jantung Kronik. Dalam Harimurti, GM. Aspek Metabolik Pada Penyakit Kardiovaskular. Jakarta. Bagian Kardiologi Fakultas Kedokteran Universitas Indonesia. 2002: 1.

9. Joesoef A. Gagal Jantung. PJNHK. Ethical Digest, No. 29, Th IV; 2007. 10. Departemen Kesehatan Republik Indonesia. Profil Kesehatan Indonesia

2008. Jakarta. 2009: 62.

11. Ghanie A. Gagal Jantung Kronik. Dalam Sudoyo AW, Setiyohadi B, Alwi I, Simadibrata M, Setiati S, editor. Buku Ajar Ilmu Penyakit Dalam Edisi 4. Jakarta: Pusat Penerbitan Ilmu Penyakit Dalam; 2010: 1601.

(2)

12. Frishman WH, Cheng-Lai A, Nawarskas J. Current Cardiovascular Drugs. Current Science Group; 2005: 152.

13. Arcangelo VP, Peterson AM. Pharmacotherapeutics for advanced practice: a practical approach. Lippincott Williams & Wilkins; 2006: 205.

14. Freemantle N, Cleland J, Young P, Mason J, Harrison J. β Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ [Internet]. 1999 [cited 2013 Oct 28]; 318(7200): 1730. Available from :

http://www.bmj.com/content/318/7200/1730.

15. Cruickshank JM. β blockers in hypertension. The Lancet [Internet]. 2010 [cited 2013 Nov 1]; 376(9739): 415. Available from :

http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)61217-2/fulltext.

16. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999; 353: 9–13.

17. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999; 353: 2001–7.

18. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996; 334: 1349–55.

19. Komajdaa M, Follath F, Swedberg K et al. The EuroHeart Failure Survey programme—a survey on the quality of care among patients with heart failure in Europe Part 2: treatment. Eur Heart J [Internet]. 2002 [cited 2013 Nov 1]; 24(5): 464-74. Available from :

http://eurheartj.oxfordjournals.org/content/24/5/464.

20. Kalra PR, Morley C, Barnes S et al. Discontinuation of beta-blockers in cardiovascular disease: UK primary care cohort study. International Journal of Cardiology [Internet]. 2012 [cited 2013 Nov 2]; 167(6): 2695-9. Available from : http://www.internationaljournalofcardiology.com/article/S0167-5273(12)00907-2/abstract .

(3)

21. Regmi S, Maskey A, Dubey L. Profile of heart failure study in patients admitted in MICU. Nepalese Heart Journal. 2009; 6 : 35–8.

22. Braunwald E, Colucci WS. Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia, 6th ed. PA: WB Saunders; 2001: 503.

23. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005; 112(12):e154-e235.

24. National Collaborating Centre for Chronic Conditions. Chronic heart failure. National Clinical Guideline for diagnosis and Management in Primary and Secondary Care. (Clinical Guideline 5.) London: National Institute for Clinical Excellence (NICE); 2003:1-163.

25. Panggabean MM. Gagal Jantung. Dalam Sudoyo AW, Setiyohadi B, Alwi I, Simadibrata M, Setiati S, editor. Buku Ajar Ilmu Penyakit Dalam. Edisi 4. Jakarta: Pusat Penerbitan Ilmu Penyakit Dalam; 2006: 1513-4.

26. Braunwald E. Heart Failure and Cor Pulmonale. Dalam Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, editor. Harrison’s Principle of Internal Medicine. Edisi 16. New York: McGraw Hill; 2005: 1367-78.

27. Tierney LM; McPhee SJ, Papadakis MA. Lange, Current Medical Diagnosis and Treatment. New York: McGraw Hill; 2002: 429-30.

28. George AL Jr. Inherited disorders of voltage-gated sodium channels. J Clin Invest [Internet]. 2005 [cited 2014 Jan 20]; 115(8): 1990-9. Available from :

http://www.ncbi.nlm.nih.gov/pubmed/16075039 .

29. Priori SG, Napolitano C. Cardiac and skeletal muscle disorders caused by mutations in the intracellular Ca2+ release channels. J Clin Invest [Internet]. 2005 [cited 2014 Jan 20]; 115(8): 2033–8. Available from :

(4)

30. Bonow RO, Mann DL, Zipes DP, Libby P. Pathophysiology of Heart Failure. In : Bonow RO, Mann DL, Zipes DP, Libby P, Braunwald E (eds). Braunwald's Heart Disease 9th Ed. Philadelphia: Elsevier Saunders; 2012. 494-5.

31. Bonow RO, Mann DL, Zipes DP, Libby P. Pathophysiology of Heart Failure. In : Bonow RO, Mann DL, Zipes DP, Libby P, Braunwald E (eds). Braunwald's Heart Disease 9th Ed. Philadelphia: Elsevier Saunders; 2012. 502.

32. Panggabean MM. Gagal Jantung. Dalam Sudoyo AW, Setiyohadi B, Alwi I, Simadibrata M, Setiati S, editor. Buku Ajar Ilmu Penyakit Dalam. Edisi 4. Jakarta: Pusat Penerbitan Ilmu Penyakit Dalam; 2010: 1583-4.

33. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med [Internet]. 1971 [cited 2014 Jan 23]; 285:1441–6. Available from :

http://www.ncbi.nlm.nih.gov/pubmed/5122894

34. Siswanto BB, Dharma S, Juzan DA, Sukmawan R. Pedoman Tatalaksana Penyakit Kardiovaskuler di Indonesia. Jakarta: Perhimpunan Dokter Spesialis Kardiovaskuler Indonesia. 2009: 267-8.

35. Dickenstein K, Cohen-Solal A, Filippatos G, McMurray JJV, Ponikowski P, Poole-Wilson PA, et al. ESC Guideline for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J. 2008; 29: 2389-90.

36. McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Bӧhm M, Dickstein K, et al. ESC Guideline for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J. 2012; 33: 1791.

37. Ghanie A, Gagal Jantung Kronik. Dalam Sudoyo AW, Setiyohadi B, Alwi I, Simadibrata M, Setiati S, editor. Buku Ajar Ilmu Penyakit Dalam. Edisi 4. Jakarta: Pusat Penerbitan Ilmu Penyakit Dalam; 2010: 1596-7.

38. McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Bӧhm M, Dickstein K, et al. ESC Guideline for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J. 2012; 33: 1794-803.

(5)

39. McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Bӧhm M, Dickstein K, et al. ESC Guideline for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J. 2012; 33: 1804-15.

40. Brunton LL, Blumenthal DK, Buxton IL, Parker KL. Agonis dan Antagonis Adrenergik. Dalam : Manurung J, Aini N, Hadinata AH, Fazriyah Y, Vidhayanti H, editor. Goodman and Gilman's Manual Farmakologi dan Terapi. : McGraw Hill; 2008: 161-2.

41. Chen-Izu Y, Xiao RP, Izu LT, Cheng H, Kuschel M, Spurgeon H, Lakatta EG. G(i)-dependent localization of beta(2)-adrenergic receptor signaling to L-type Ca(2+) channels. Biophys J [Internet]. 2000 [cited 2014 Jan 25]; 79(5): 2547–56. Available from : http://www.ncbi.nlm.nih.gov/pubmed/11053129 . 42. Brunton LL, Blumenthal DK, Buxton IL, Parker KL. Agonis dan Antagonis

Adrenergik. Dalam : Manurung J, Aini N, Hadinata AH, Fazriyah Y, Vidhayanti H, editor. Goodman and Gilman's Manual Farmakologi dan Terapi. : McGraw Hill; 2008: 163-70.

44. Opie LH, Gersh BJ. β-Blocking Agents. In: Opie LH, Gersh BJ (eds). Drugs for the Heart 6th Ed. Philadelphia: Elsevier Saunders; 2005. 20-1.

45. Katzung BG, Masters SB, Trevor AJ. Adrenoceptor Antagonist Drugs. Basic & Clinical Pharmacology , 12th ed. : McGraw Hill; 2012: 162-4

(6)

49.Octavian C, Albinita C, Liciniu V, Marius P. Medical And Social Care of Old Age Persons.Oradea. 2010: 1.

50. Gislason GH, Rasmussen JN, Abildstrom SZ, Schramm TK, Hansen ML, Buch P et al.. Persistent Use of Evidence-Based Pharmacotherapy in Heart Failure Is Associated With Improved Outcomes. Circulation 2007; 116: 739. Available from : http://www.circ.ahajournals.org/ (Accessed 3 July 2014). 51.Go AS, Mozaffarian D, Roger VL et al. Heart disease and stroke statistics –

2014 update: a report from the American Heart Association. Circulation 2014;129:e28–e292

52.Townsend N, Wickramasinghe K, Bhatnagar P et al. Coronary heart disease statistics (2012 edition). London: British Heart Foundation, 2012. Available

from :

http://www.bhf.org.uk/publications/view-publication.aspx?ps=1002097 (Accessed 8 July 2014).

53. Ceia F, Fonseca C, Mota T et al. Prevalence of chronic heart failure in Southwestern Europe: the EPICA study. Eur J Heart Fail 2002;4:531–9. 54. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart

failure. Nat Rev Cardiol 2011;8:30–41.

55.Atherton JJ, Hayward CS, Wan Ahmad WA et al. Patient characteristics from a regional multicenter database of acute decompensated heart failure in Asia Pacific (ADHERE International-Asia Pacific). J Card Fail 2012;18:82–8. 56.Bocchi EA. Heart failure in South America. Curr Cardiol Rev 2013;9:147–56. 57. Global Atlas on Cardiovascular Disease Prevention and Control. Mendis S,

Puska P, Norrving B editors. World Health Organization (in collaboration with the World Heart Federation and World Stroke Organization), Geneva 2011: 62.

58. Tse WY, Kendall M : Is there a role for beta-blockers in hypertensive diabetic patients? Diabet Med 1994; 11: 137-44.

59. Bell DS : Optimizing treatment of diabetes and cardiovascular disease with combined alpha,beta-blockade. Curr Med Res Opin 2005; 21: 1191-200. 60. Barnett AH, Leslie D, Watkins PJ : Can insulin-treated diabetics be given

(7)

61. British Journal of Anaesthesia. Recommendations on perioperative b-blockers: differing guidelines: so what should the clinician do?. 2010; 104(3): 273-5. 62. Jansson S, Lie-Karlsen K, Stenqvist O, Korner U, Lundholm K, Tisell LE.

Oxygen consumption in patients with hyperthyroidism before and after treatment with beta-blockade versus thyrostatic treatment: a prospective randomized study. Ann Surg. 2001;233:60–4.

63. Life Expectancy At Birth. 2014. Available from :

https://www.cia.gov/library/publications/the-world-factbook/rankorder/2102rank.html (accessed 21st July 2014).

64. Sakata Y, Shimokawa H. Epidemiology of heart failure in Asia. Circ J 2013;77:2209–17.

65. Huffman MD, Prabhakaran D. Heart failure: epidemiology and prevention in India. Natl Med J India 2010;23:283–8.

66. Sasayama S. Heart disease in Asia. Circulation. 2008; 118: 2669–71.

67. Bocchi EA, Braga FG, Ferreira SM et al. [III Brazilian guidelines on chronic heart failure]. Arq Bras Cardiol. 2009; 93: 3–70.

(8)

(9)

(10)

(11)

Lampiran 4. Data Output SPSS Versi 22

Jenis_kelamin

Frequency Percent Valid Percent

Cumulative Percent Valid laki-laki 116 54,2 54,2 54,2 perempuan 98 45,8 45,8 100,0 Total 214 100,0 100,0 Statistics Usia N Valid 214 Missing 0 Mean 56,41 Std. Deviation 13,466 Minimum 17 Maximum 85 Klasifikasi Usia

Cumulative Percent Valid 13-18 1 ,5 ,5 ,5 19-59 133 62,1 62,1 62,6 60-64 26 12,1 12,1 74,8 65-90 54 25,2 25,2 100,0 Total 214 100,0 100,0

(12)

jaminan_kesehatan_sosial

Cumulative Percent Valid ASKES 80 37,4 37,4 37,4 jamkesda 9 4,2 4,2 41,6 jamkesmas 41 19,2 19,2 60,7 jampersal 2 ,9 ,9 61,7 jamsostek 1 ,5 ,5 62,1 tanggungan pribadi 81 37,9 37,9 100,0 Total 214 100,0 100,0 beta_blocker

Cumulative Percent

Valid bisoprolol 52 24,3 24,3 24,3

bisoprolol (lalu distop karena

syok kardiogenik) 1 ,5 ,5 24,8

bisoprolol (lalu distop) 1 ,5 ,5 25,2

carvedilol 12 5,6 5,6 30,8

carvedilol (lalu distop karena

hipotensi) 1 ,5 ,5 31,3

propranolol 2 ,9 ,9 32,2

tidak dapat 144 67,3 67,3 99,5

tidak dapat (bisoprolol

diusulkan) 1 ,5 ,5 100,0

(13)

alasan_tidak_dapat_beta_blocker

Cumulative Percent Valid 69 32,2 32,2 32,2 asma 3 1,4 1,4 33,6 bradikardia 1 ,5 ,5 34,1 hipotensi 5 2,3 2,3 36,4 kongesti 21 9,8 9,8 46,3 kongesti, bradikardia 1 ,5 ,5 46,7 syok kardiogenik 3 1,4 1,4 48,1

syok kardiogenik, kongesti 2 ,9 ,9 49,1

syok septik, cardiac arrest, terapi spironolactone sebagai diuretik curiga kongesti

1 ,5 ,5 49,5

syok septik, kongesti 1 ,5 ,5 50,0

terapi furosemide & spironolactone sebagai diuretik curiga kongesti

5 2,3 2,3 52,3

terapi furosemide curiga

kongesti 52 24,3 24,3 76,6

kongesti, asma 2 ,9 ,9 77,6

kongesti, hipotensi 4 1,9 1,9 79,4

terapi furosemide curiga kongesti, hipotensi, bradikardia

1 ,5 ,5 79,9

terapi furosemide curiga kongesti, terapi ivabradine curiga kontraindikasi / intoleransi beta blocker

1 ,5 ,5 80,4

terapi HCT curiga kongesti 3 1,4 1,4 81,8

terapi ivabradine curiga kontraindikasi / intoleransi beta blocker

1 ,5 ,5 82,2

terapi spironolactone sebagai diuretik curiga kongesti

(14)

tidak diketahui 34 15,9 15,9 99,5 tidak diketahui (diusulkan

bisoprolol) 1 ,5 ,5 100,0

Total 214 100,0 100,0

furosemide

Cumulative Percent

Valid dapat 116 54,2 54,2 54,2

diusulkan bila sistole

>100 1 ,5 ,5 54,7

tidak dapat 96 44,9 44,9 99,5

tidak dapat (diusulkan) 1 ,5 ,5 100,0

Total 214 100,0 100,0

hydrochlorothiazide

Cumulative Percent Valid dapat 6 2,8 2,8 2,8 tidak dapat 208 97,2 97,2 100,0 Total 214 100,0 100,0 nitrat

Cumulative Percent

Valid dapat 87 40,7 40,7 40,7

diusulkan jika sistole

>110 1 ,5 ,5 41,1

tidak dapat 126 58,9 58,9 100,0

(15)

ACE_inhibitor

Cumulative Percent

Valid captopril 81 37,9 37,9 37,9

captopril (ditunda karena

batuk) 1 ,5 ,5 38,3

captopril (lalu distop) 5 2,3 2,3 40,7

lisinopril 5 2,3 2,3 43,0

perindopril 1 ,5 ,5 43,5

ramipril 13 6,1 6,1 49,5

ramipril (lalu distop) 1 ,5 ,5 50,0

tidak dapat 107 50,0 50,0 100,0

Total 214 100,0 100,0

ARB

Cumulative Percent

Valid candesartan 21 9,8 9,8 9,8

candesartan (lalu distop) 2 ,9 ,9 10,7

irbesartan 4 1,9 1,9 12,6

irbesartan diusulkan bila

sistole >100 1 ,5 ,5 13,1 telmisartan 1 ,5 ,5 13,6 tidak dapat 151 70,6 70,6 84,1 valsartan 34 15,9 15,9 100,0 Total 214 100,0 100,0 Dobutamine

Cumulative Percent Valid dapat 11 5,1 5,1 5,1 tidak dapat 202 94,4 94,4 99,5 tidak dapat (diusulkan) 1 ,5 ,5 100,0 Total 214 100,0 100,0

(16)

Digoxin

Cumulative Percent

Valid dapat 89 41,6 41,6 41,6

dapat (lalu distop) 1 ,5 ,5 42,1

tidak dapat 124 57,9 57,9 100,0

Total 214 100,0 100,0

Spironolactone

Cumulative Percent

Valid dapat 140 65,4 65,4 65,4

dapat (diuretik ->

normal) 1 ,5 ,5 65,9

dapat (lalu distop) 1 ,5 ,5 66,4

dapat (sebagai diuretik) 20 9,3 9,3 75,7

tidak dapat 51 23,8 23,8 99,5

tidak dapat (diusulkan) 1 ,5 ,5 100,0

Total 214 100,0 100,0

kesesuaian_beta_blocker

Cumulative Percent Valid 145 67,8 67,8 67,8 sesuai indikasi 58 27,1 27,1 94,9 sesuai indikasi, kontraindikasi ancaman gagal nafas 1 ,5 ,5 95,3 sesuai indikasi, kontraindikasi bradikardia 1 ,5 ,5 95,8 sesuai indikasi, kontraindikasi hipotensi 3 1,4 1,4 97,2

(17)

sesuai indikasi,

kontraindikasi kongesti 2 ,9 ,9 98,1

tidak sesuai indikasi (dosis

di bawah dosis awal) 2 ,9 ,9 99,1

tidak sesuai indikasi

(propranolol) 2 ,9 ,9 100,0

(18)

Lampiran 5. Biodata Mahasiswa Identitas

Nama : Christian Suryajaya

NIM : 22010110120086

Tempat/tanggal lahir : Jakarta, 10 Januari 1992 Jenis kelamin : laki-laki

Alamat : Jl. Melati Utara No. 7, Semarang

Nomor HP : 0817856644

e-mail : chrizz_92@hotmail.com Riwayat Pendidikan Formal

1. SD : SD St. Yakobus Jakarta Lulus tahun : 2004 2. SMP : SMP St. Yakobus Jakarta Lulus tahun : 2007 3. SMA : SMAK 5 BPK Penabur Jakarta Lulus tahun : 2010 4. FK UNDIP : Masuk tahun : 2010

Keanggotaan Organisasi

1. Asisten mahasiswa bagian anatomi FK UNDIP tahun 2012 s/d 2014. 2. PRMK FK UNDIP tahun 2010 s/d 2014.